- The trend backdrop is active with a 1-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
ESF0
GER
Week ended 07 Aug 2026
Weekly Investor Report
Eurofins Scientific SE · Healthcare · Diagnostics & Research
Latest close
69.86 EUR
3.4%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 7.3% above the Trend Line and sits at 85.5% of its 52-week range. The latest completed week returned 3.4%, after a 1.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 59/100.
Setup score
57
out of 100
Latest Close
69.86 EUR
7 Aug 2026
1W Return
3.4%
latest completed week
4W Return
1.5%
short-term follow-through
12W Return
18.3%
quarterly tape
Trend Breadth
44.2%
23 of 52 weeks active
Volume Ratio
3.0x
vs 13-week average
- Next-week expectancy is negative at 44.11% based on similar historical setup states.
- 2 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.4%
Latest completed week; four-week move 1.5%.
Indicator stack
28/72
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 44.11%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
59/100
4 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 7.3% above the Trend Line and sits at 85.5% of its 52-week range. The latest completed week returned 3.4%, after a 1.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 3.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.5812-week average 0.34
12-week confirmation
Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.58Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 1.5% over four weeks, 18.3% over 12 weeks, and 8.5% over one year. The current trend has remained active for 1 consecutive weeks.
Performance by holding period
Active trend streak1 weeks
Active weeks in one year23
Trend breadth44.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.90Latest activity-pressure read.
Pressure change75.5%Four-week change in activity pressure.
Leadership1.76Latest relative-leadership reading.
RS change-66.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 91%
Model confidence 72%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength60/100Blend of value, momentum, and quality. Underlying universe rank 41; rank 1 is best.
Value34/100Relative valuation strength. Underlying universe rank 67; rank 1 is best.
Quality83/100Profitability and accounting quality. Underlying universe rank 18; rank 1 is best.
Momentum59/100Medium-term price momentum. Underlying universe rank 42; rank 1 is best.
Growth77/100Revenue and earnings growth. Underlying universe rank 24; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework39/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 25.4x Price divided by trailing earnings.
- Price / sales
- 1.7x Market value relative to trailing revenue.
- EV / EBITDA
- 10.3x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 68.1% Gross profit retained from each unit of revenue.
- Operating margin
- 11.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 7.7% Free cash flow generated from revenue.
- Return on invested capital
- 7.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 5.0% Latest one-year revenue growth.
- EPS growth
- 23.5% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -28.6% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 1.0% Cash dividends relative to market value.
- Buyback yield
- 4.5% Net share repurchases relative to market value.
- Shareholder yield
- 5.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment59/100
Weighted news tone is neutral across 4 relevant articles.
3 positive · 0 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-3.5%Distance below the 52-week high.
13-week volatility3.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher14 of 2612 weeks finished lower.
Best week+10.1%Week of 17 Apr.
Worst week-12.1%Week of 24 Apr.
Latest week+3.4%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains9
Flat weeks0
Modest losses7
Sharp losses5
Recent vol3.2%13-week weekly-return volatility.
Base vol4.0%52-week weekly-return volatility.
Up/down split26/25Count of positive and negative weeks in the 52-week window.
Average skew3.2% / -2.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank32 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Diagnostics & Research
4-week rank3 / 6
Group average1.9%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD100.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape52/100
Trend, activity pressure, participation, and risk combine to a 52/100 tape read.
Indicator analysis42/100Latest 12-week confirmation: trend 1/12, activity pressure 7/12, relative leadership 8/12.
Activity pressure 0.58; 2 reversal markers Next-Week ExpectancyNegative 44.11%Next-week expectancy is negative with a 44.11% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors59/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 9; Small Cap Core rank 52 SVQF39/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 228.5 of 375 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment59/100Weighted news tone is neutral across 4 relevant articles.
Thermo Fisher Scientific (TMO) Reports Strong Q2 Earnings with R Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 69.86 EUR | 3.4% | 65.11 EUR | 56.10 EUR | 0.90 | 1.76 | 2.9K | On |
| 31 Jul 2026 | 67.58 EUR | -2.8% | 65.07 EUR | 56.01 EUR | 0.76 | 1.08 | 335 | Off |
| 24 Jul 2026 | 69.50 EUR | 0.2% | 64.88 EUR | 55.94 EUR | 0.77 | 5.99 | 3.8K | Off |
| 17 Jul 2026 | 69.34 EUR | 0.8% | 64.59 EUR | 55.88 EUR | 0.67 | 6.80 | 71 | Off |
| 10 Jul 2026 | 68.82 EUR | -0.5% | 64.32 EUR | 55.81 EUR | 0.51 | 5.25 | 439 | Off |
| 3 Jul 2026 | 69.20 EUR | 1.6% | 63.93 EUR | 55.73 EUR | 0.30 | 3.12 | 32 | Off |
| 26 Jun 2026 | 68.12 EUR | 6.9% | 63.57 EUR | 55.64 EUR | 0.11 | 6.18 | 100 | Off |
| 19 Jun 2026 | 63.74 EUR | 1.0% | 63.21 EUR | 55.55 EUR | -0.13 | -1.72 | 94 | Off |
| 12 Jun 2026 | 63.08 EUR | -4.1% | 63.00 EUR | 55.49 EUR | -0.30 | -1.32 | 787 | Off |
| 5 Jun 2026 | 65.80 EUR | 5.5% | 62.81 EUR | 55.46 EUR | -0.45 | 2.44 | 22 | Off |
| 29 May 2026 | 62.36 EUR | -0.6% | 62.53 EUR | 55.40 EUR | -0.65 | -4.01 | 2.0K | Off |
| 22 May 2026 | 62.72 EUR | 6.2% | 62.46 EUR | 55.38 EUR | -0.80 | -2.56 | 194 | Off |
| 15 May 2026 | 59.06 EUR | 0.7% | 62.45 EUR | 55.35 EUR | -0.74 | -4.53 | 2.1K | Off |
| 8 May 2026 | 58.66 EUR | 0.5% | 62.51 EUR | 55.34 EUR | -0.60 | -6.58 | 1.8K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.